SoluBest was founded in 2001 to develop an easy-to-integrate technological platform for solving one of the most pressing issues facing the Pharma industry: the problem of drug insolubility.
Privately owned and funded, SoluBest has recently concluded its 4th round of financing.
SoluBest is pursuing a Two-Pronged Business Model:
On one hand, Solubest establishes multiple customized services through leverage on its expertise in the development of challengeable formulations. This ongoing model results in short term income and long term royalties based income, and/or supply opportunities in Pharma and non-Pharma applications (Nutraceuticals, Agro, and so forth).
On the other hand Solubest spins off the matured, in vivo and/or clinically proven products into new ventures focused on product approvals and commercialization. Such a model adds value through equity-based joint ventures, and/or licensing-out agreements based on down- and milestones-payments. Several JVs are currently being formed.
THIS EXECUTIVE SUMMARY IS FURNISHED TO POTENTIAL INVESTORS AS INITIAL GENERAL INFORMATION ABOUT THE SOLUBEST CLUSTER AND ITS DEVELOPMENT PLANS, "AS IS" AND WITHOUT MAKING ANY WARRANTY. THIS DOCUMENT CONTAINS PROPRIETARY AND CONFIDENTIAL FINANCIAL AND TECHNICAL INFORMATION PERTAINING TO SOLUBEST. ANY USE OF THIS DOCUMENT FOR ANY OTHER PURPOSE
THAN THE EXPRESSED PURPOSE FOR WHICH IT WAS INTENDED IS FORBIDDEN.
| SoluBest Ltd., Weizmann Science Park, POB 4053 18 Einstein Street, Ness Ziona 74140, Israel |
| Tel: +972-8-940-3023 | Fax: +972-8-930-2878 | email@example.com |